Experts discuss evolving treatment strategies for metastatic castration-resistant prostate cancer, emphasizing personalized therapy and innovative options.
The Genomic Prostate Score (GPS) is being validated in the ProtecT trial to predict prostate cancer progression and treatment outcomes. ProtecT is a landmark phase 3 trial with over 1600 men, ...
Heidegger emphasizes that sexual concerns are almost never purely biological or purely psychological—they are biopsychosocial. In this episode of Pearls & Perspectives, Amy Pearlman, MD, sits down ...
The expert faculty emphasize the growing importance of multidisciplinary collaboration and workforce development as NMIBC management evolves to include systemic immunotherapies. The expert faculty ...
The Decipher Genomic Classifier effectively predicts 2-year BCR in localized prostate cancer, especially in African American men, with an AUC of 0.889, increasing to 0.984 after adjustments. High-risk ...
The J9282 code for ZUSDURI facilitates billing and reimbursement, improving patient access to bladder cancer treatment. ZUSDURI, approved by the FDA in June 2025, is the first medication for recurrent ...
Daniel Spratt, MD, discusses how the ArteraAI Prostate Test (Post-RP) could help guide treatment intensification decisions. On December 9, 2025, Artera announced the commercial launch of the ArteraAI ...
GSK resubmitted an NDA for tebipenem pivoxil hydrobromide to the FDA for cUTI treatment, including pyelonephritis. The phase 3 PIVOT-PO trial showed tebipenem HBr's noninferiority to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback